FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Italy Fines Apple €98.6 Million Over App Store Dominance 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Novartis AG announced on Monday, Feb. 5, that it has acquired MorphoSys. The Basel, Switzerland-based pharmaceutical corporation agreed to buy the cancer drug developer for $2.9 billion or €2.7 billion.
As per Reuters, Novartis will offer shareholders €68 per share in cash. It also revealed its plan to take MorphoSys private once the deal is completed. Upon closing the transaction, which is expected within the first two quarters of this year, Novartis will now own pelabresib.
MorphoSys' Pelabresib Drug
This treatment has been described as one of the most promising cancer drugs. It is used to combat life-threatening forms of the intrusive disease. It was mentioned that pelabresib could be used for the treatment of rare bone marrow cancer called myelofibrosis and other types of lumpy lymphomas.
Through its purchase of MorphoSys, Novartis can bolster its oncology portfolio. This merger marks Novartis's first M&A deal this year. It was speculated earlier in January that it would buy Cytokinetics biotech firm, but the deal did not proceed.
Details of Transaction
Their respective Board unanimously approved the acquisition deal between Novartis and MorphoSys of Directors. While awaiting the final closing of the transaction, MorphoSys will continue to operate its business independently.
"We are excited about the opportunity of bringing pelabresib, a potential next-generation treatment combined with ruxolitinib, to people living with myelofibrosis, a rare and debilitating form of blood cancer," Novartis' president of development and chief medical officer, Shreeram Aradhye, M.D., said in a press release. "With the planned acquisition of MorphoSys, we aim to further strengthen our leading pipeline and portfolio in oncology, adding to our capabilities and expertise."
He added, "Building on our long-standing development partnership with MorphoSys, we look forward to continuing our work together to realize the full impact and value of their investigational medicines for patients with unmet needs."
Photo by: Novartis Media Library
